This compelling scientific event is dedicated to exploring the rapidly evolving field of HER2-positive metastatic breast cancer research, encompassing groundbreaking treatments, and addressing critical challenges. With the advent of innovative therapies such as trastuzumab-deruxtecan and novel tyrosine kinase inhibitors (TKIs), the landscape of HER2-positive breast cancer management is experiencing transformative advancements.

The event will commence with a captivating keynote lecture by a renowned expert, providing an in-depth analysis of the latest breakthroughs and ongoing research efforts in HER-2-positive metastatic breast cancer. The focus will extend to new treatment modalities, spotlighting their mechanisms of action and potential benefits.

During the interactive Q&A session, participants will have the opportunity to engage with leading researchers and clinicians, exploring pressing topics such as the management of elderly patients with HER-2-positive metastatic breast cancer, the prevention and monitoring of Intestinal Lung Disease (ILD), and optimal strategies for patients with brain metastases.

A key highlight of the event will be the presentation and collective discussion of real-life clinical cases. Experts and attendees will collaboratively analyze and debate various treatment approaches, taking into account patient-specific factors, treatment responses, and potential side effects. This interactive approach will foster valuable insights and facilitate knowledge-sharing among attendees.

Emphasizing the multidisciplinary nature of managing HER-2-positive metastatic breast cancer, this event will serve as a platform to accelerate scientific advancements and enhance the quality of care for patients affected by this challenging disease.